Again, FDA review in pre-submission discussion program is a review of whatever RDGL has submitted with goal of FDA making helpful suggestions for a stronger IDE application down road. Until the IDE application is submitted, FDA is not reviewing the device for human trials.
RDGL's Twitter statement "Our (PRnT) device is currently undergoing review with the @US_FDA." is false.
News 
Market Data 
Discover 
